Julie J. Kim

FDA Accelerates Again: The Second CNPV Cohort

Onshoring Drug Manufacturing: Insights From FDA's PreCheck Initiative And Public Meeting

You've Got Mail, And Twice The Time To Respond! Two Device Companies Find Themselves With 30 Business Days To Respond To FDA's Warning Letters

The ICH E6(R3) Guideline: A Major Update To Good Clinical Practice